1. Home
  2. BNTX vs NTRA Comparison

BNTX vs NTRA Comparison

Compare BNTX & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNTech SE

BNTX

BioNTech SE

HOLD

Current Price

$88.79

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$195.66

Market Cap

28.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNTX
NTRA
Founded
2008
2003
Country
Germany
United States
Employees
N/A
6140
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2B
28.2B
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
BNTX
NTRA
Price
$88.79
$195.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
15
Target Price
$133.46
$259.07
AVG Volume (30 Days)
855.0K
1.4M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
N/A
$18.08
Revenue Next Year
$3.37
$19.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$79.81
$131.81
52 Week High
$124.00
$256.36

Technical Indicators

Market Signals
Indicator
BNTX
NTRA
Relative Strength Index (RSI) 34.66 45.98
Support Level $84.78 $187.27
Resistance Level $112.44 $220.74
Average True Range (ATR) 3.11 11.08
MACD -1.20 -1.72
Stochastic Oscillator 7.03 27.70

Price Performance

Historical Comparison
BNTX
NTRA

About BNTX BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: